Randall Schreck
About
In The Last Decade
Randall Schreck
13 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Molecular Biology 1.5k
- Oncology 686
- Cancer Research 469
- Pulmonary and Respiratory Medicine 318
- Hepatology 298
Countries citing papers authored by Randall Schreck
This map shows the geographic impact of Randall Schreck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall Schreck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall Schreck more than expected).
Fields of papers citing papers by Randall Schreck
This network shows the impact of papers produced by Randall Schreck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall Schreck. The network helps show where Randall Schreck may publish in the future.
Co-authorship network of co-authors of Randall Schreck
This figure shows the co-authorship network connecting the top 25 collaborators of Randall Schreck. A scholar is included among the top collaborators of Randall Schreck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall Schreck. Randall Schreck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 2 | |
| 3 | 4 | |
| 4 | A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. | 421 |
| 5 | High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. | 60 |
| 6 | The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. | 173 |
| 7 | 99 | |
| 8 | SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. breakdown → | 885 |
| 9 | 213 | |
| 10 | Flk-1 as a target for tumor growth inhibition. | 279 |
| 11 | 49 | |
| 12 | 98 | |
| 13 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.